BACKGROUND: BARD1 was originally identified as a BRCA1-interacting protein but has also been described in tumour-suppressive functions independent of BRCA1. Several studies have indicated that the BARD1 gene is a potential target for germline changes predisposing to breast and ovarian cancer. The C-terminal Cys557Ser change has previously been uncovered to associate with an increased risk of breast cancer and was recently shown to result in defective apoptotic activities. AIM AND METHODS: Conformation-sensitive gel electrophoresis, minisequencing, TaqMan assays, denaturing high-performance liquid chromatography analysis and DNA sequencing were used to investigate the prevalence of the Cys557Ser allele in a large Nordic case-control study cohort consisting of 2906 patients with breast or ovarian cancer, 734 with prostate cancer, 188 with colorectal cancer, 128 men with breast cancer, and 3591 controls from Finland, Iceland, Denmark, Sweden and Norway. RESULTS: The frequency of the BARD1 Cys557Ser variant seemed to increase among patients from families with breast or ovarian cancer lacking BRCA1 or BRCA2 mutations: a significant difference was obtained compared with controls (6.8% v 2.7%; p<0.001; odds ratio (OR) 2.6; 95% confidence interval (CI) 1.7 to 4.0) and with patients from BRCA1/BRCA2 mutation-positive families (6.8% v 2.2%; p = 0.01; OR 3.2; 95% CI 1.2 to 8.3). In contrast, no major association with male breast, ovarian, colorectal or prostate cancer was observed. Additionally, a novel BARD1 allele resulting in Ser558Pro was identified in familial breast cancer cases. CONCLUSION: These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.
BACKGROUND:BARD1 was originally identified as a BRCA1-interacting protein but has also been described in tumour-suppressive functions independent of BRCA1. Several studies have indicated that the BARD1 gene is a potential target for germline changes predisposing to breast and ovarian cancer. The C-terminal Cys557Ser change has previously been uncovered to associate with an increased risk of breast cancer and was recently shown to result in defective apoptotic activities. AIM AND METHODS: Conformation-sensitive gel electrophoresis, minisequencing, TaqMan assays, denaturing high-performance liquid chromatography analysis and DNA sequencing were used to investigate the prevalence of the Cys557Ser allele in a large Nordic case-control study cohort consisting of 2906 patients with breast or ovarian cancer, 734 with prostate cancer, 188 with colorectal cancer, 128 men with breast cancer, and 3591 controls from Finland, Iceland, Denmark, Sweden and Norway. RESULTS: The frequency of the BARD1 Cys557Ser variant seemed to increase among patients from families with breast or ovarian cancer lacking BRCA1 or BRCA2 mutations: a significant difference was obtained compared with controls (6.8% v 2.7%; p<0.001; odds ratio (OR) 2.6; 95% confidence interval (CI) 1.7 to 4.0) and with patients from BRCA1/BRCA2 mutation-positive families (6.8% v 2.2%; p = 0.01; OR 3.2; 95% CI 1.2 to 8.3). In contrast, no major association with male breast, ovarian, colorectal or prostate cancer was observed. Additionally, a novel BARD1 allele resulting in Ser558Pro was identified in familial breast cancer cases. CONCLUSION: These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.
Authors: R Dechend; F Hirano; K Lehmann; V Heissmeyer; S Ansieau; F G Wulczyn; C Scheidereit; A Leutz Journal: Oncogene Date: 1999-06-03 Impact factor: 9.867
Authors: Pia Vahteristo; Kirsi Syrjäkoski; Tuomas Heikkinen; Hannaleena Eerola; Kristiina Aittomäki; Karl von Smitten; Kaija Holli; Carl Blomqvist; Olli-Pekka Kallioniemi; Heli Nevanlinna Journal: Eur J Hum Genet Date: 2006-02 Impact factor: 4.246
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: David Fox; Isolde Le Trong; Ponni Rajagopal; Peter S Brzovic; Ronald E Stenkamp; Rachel E Klevit Journal: J Biol Chem Date: 2008-05-14 Impact factor: 5.157
Authors: Amanda B Spurdle; Louise Marquart; Lesley McGuffog; Sue Healey; Olga Sinilnikova; Fei Wan; Xiaoqing Chen; Jonathan Beesley; Christian F Singer; Anne-Catharine Dressler; Daphne Gschwantler-Kaulich; Joanne L Blum; Nadine Tung; Jeff Weitzel; Henry Lynch; Judy Garber; Douglas F Easton; Susan Peock; Margaret Cook; Clare T Oliver; Debra Frost; Don Conroy; D Gareth Evans; Fiona Lalloo; Ros Eeles; Louise Izatt; Rosemarie Davidson; Carol Chu; Diana Eccles; Christina G Selkirk; Mary Daly; Claudine Isaacs; Dominique Stoppa-Lyonnet; Olga M Sinilnikova; Bruno Buecher; Muriel Belotti; Sylvie Mazoyer; Laure Barjhoux; Carole Verny-Pierre; Christine Lasset; Hélène Dreyfus; Pascal Pujol; Marie-Agnès Collonge-Rame; Matti A Rookus; Senno Verhoef; Mieke Kriege; Nicoline Hoogerbrugge; Margreet G E M Ausems; Theo A van Os; Juul Wijnen; Peter Devilee; Hanne E J Meijers-Heijboer; Marinus J Blok; Tuomas Heikkinen; Heli Nevanlinna; Anna Jakubowska; Jan Lubinski; Tomasz Huzarski; Tomasz Byrski; Francine Durocher; Fergus J Couch; Noralane M Lindor; Xianshu Wang; Mads Thomassen; Susan Domchek; Kate Nathanson; Ma Caligo; Helena Jernström; Annelie Liljegren; Hans Ehrencrona; Per Karlsson; Patricia A Ganz; Olufunmilayo I Olopade; Gail Tomlinson; Susan Neuhausen; Antonis C Antoniou; Georgia Chenevix-Trench; Timothy R Rebbeck Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-03-10 Impact factor: 4.254
Authors: Thomas Paul Slavin; Mariana Niell-Swiller; Ilana Solomon; Bita Nehoray; Christina Rybak; Kathleen R Blazer; Jeffrey N Weitzel Journal: Front Oncol Date: 2015-09-29 Impact factor: 6.244
Authors: Nana Weber-Lassalle; Julika Borde; Konstantin Weber-Lassalle; Judit Horváth; Dieter Niederacher; Norbert Arnold; Silke Kaulfuß; Corinna Ernst; Victoria G Paul; Ellen Honisch; Kristina Klaschik; Alexander E Volk; Christian Kubisch; Steffen Rapp; Nadine Lichey; Janine Altmüller; Louisa Lepkes; Esther Pohl-Rescigno; Holger Thiele; Peter Nürnberg; Mirjam Larsen; Lisa Richters; Kerstin Rhiem; Barbara Wappenschmidt; Christoph Engel; Alfons Meindl; Rita K Schmutzler; Eric Hahnen; Jan Hauke Journal: Breast Cancer Res Date: 2019-04-29 Impact factor: 6.466